THE Therapeutic Goods Administration (TGA) has announced new orphan drug designations or priority review designations, naming BioMarin's Kuvan (sapropterin) for hypothalamus-pituitary-adrenal syndrome, as well as Roche's haemophilia treatment Hemlibra (emicizumab) and Alecensa (alectinib) for small cell lung cancer.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Sep 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Sep 17